Gossamer Bio, Inc. (GOSS), Thursday announced an option agreement to acquire Respira Therapeutics and its lead product candidate, RT234, an investigational inhaled vardenafil dry-powder therapy for pulmonary hypertension.
The deal is anticipated to expand the company's pulmonary hypertension franchise, and strengthen its engagement with pulmonary hypertension clinicians and patients.
As per the terms of the deal, the clinical biopharmaceutical company will issue 2.5 million shares in connection with signing with an additional 1.5 million shares due upon exercise of the option.
Additionally, current and former shareholders of Respira will be eligible for certain success-based clinical, regulatory, and commercial milestone payments and a high single-digit royalty on potential net sales of RT234.
During the option period, Gossamer will fund certain pre-agreed development expenses for upto approximately 2 years, the company added.
In the pre-market hours, GOSS is moving down 3.01 percent, to $2.9 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.